Looking forward, thriving together – A recap of EverBridge Group's participation in the 17th China southern endovascular congress (SEC 2024)

Updates

2024.08.02

30


From July 18 to 21, 2024, the 17th China Southern Endovascular Congress (SEC 2024) was held in Guangzhou as scheduled. The conference brought together renowned doctors, professors, and experts in the field of vascular medicine from both China and abroad, engaging in in-depth discussions on clinical diagnosis and Treatment of vascular diseases, evidence-based medicine, medical innovation and transformation, and the application of new theories and technologies. Together, they explored new ideas and methods for the prevention and Treatment of vascular diseases.  


On July 19, EverBridge Group's peripheral vascular business unit, dedicated to providing comprehensive solutions for peripheral vascular disease Treatment, made its debut at SEC 2024. The group showcased its specialized peripheral vascular diagnostic and therapeutic products and clinical solutions to numerous experts and professors. The custom-designed booth combined digital and traditional elements to present the "family portrait" of EverBridge Group's peripheral vascular product line to attendees. Products on display included:  
- **Transit Pathope Vascular Sheath Set**    
- **PassGet Peripheral Vascular Guidewire**    
- **SuperGet Stiff Guidewire**    
- **Paclix Natural Paclitaxel Drug-Coated Balloon**    
- **Apexus PTA Balloon Dilatation Catheter**    
- **Hypery High-Pressure Balloon Dilatation Catheter**    
- **HuiHang PTA Balloon Dilatation Catheter**    
- **GENESIS-V01 Radiofrequency Generator**    
- **V-Cure Endovenous Radiofrequency Ablation Catheter**    
- **SonoEye P2 Full-Digital Color Handheld Doppler Ultrasound Diagnostic System*

1.EverBridge Group's peripheral vascular business unit consists of two member companies: **Polery Medical Technology (Suzhou) Co., Ltd.** and **Kunshan Resonant Medical Technology Co., Ltd.**, both focused on the R&D and production of high-value consumables for arterial and venous Treatment.

Through this exhibition, EverBridge Group's peripheral vascular business unit aimed to gather valuable feedback from professionals, deepen existing collaborations, and pioneer new opportunities for integrating scientific research with medical practice. By leveraging advanced research technologies and fostering close cooperation both domestically and internationally, the group strives to address the challenges and clinical needs in peripheral vascular disease Treatment with precision and depth. The goal is to continuously explore new paths for technological innovation, developing more efficient and accurate Treatment solutions and products, and providing advanced, high-quality, and affordable medical technologies to patients worldwide suffering from chronic vascular diseases, allowing them to share in the benefits of exceptional Treatment experiences.

On the afternoon of July 19, EverBridge Group successfully hosted the "Core Brilliance, Precision Control" peripheral vascular seminar. The seminar was divided into two sessions: arterial topics and venous topics. Numerous domestic experts and scholars delivered insightful presentations and comments, making the event a full-house success filled with valuable content. The one-hour seminar concluded with resounding applause from the audience.

Arterial Topics Session



Chaired by:  
- Professor Fang Xin, Hangzhou First People's Hospital  
- Professor Ju Shang, Dongzhimen Hospital, Beijing University of Chinese Medicine  
- Professor Yao Chen, The First of Hospital of Sun Yat-sen University  
- Professor Zhang Yan, The First of Hospital of Jinan University

Professor Ye Kaichuang, The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine:  

"The Value and Application Experience of Tapered Balloons in Lower Extremity Artery Treatment"


Professor Sun Xiaolei**, Hospital of Southwest Medical University:

"Initial Impressions of the PassGet™ Guidewire"


Professor Han Weiqiang**, Peking University International Hospital:

"Case Sharing: Treatment of Lower Extremity Arterial Occlusive Disease with PassGet, Apexus, and Paclix"


Commentary by:  
- Professor Li Chengzhi, The First Hospital of Jinan University  
- Professor Wan Jia, Hospital of Yunnan University  
- Professor Yan Sheng, Shanxi Medical University  
- Professor Yuan Liangxi, The First Hospital of Naval Medical University (Shanghai Changhai Hospital)


Venous Topics Session



Chaired by:  
- Professor Jiang Jinsong, Zhejiang Provincial People's Hospital  
- Professor Yao Chen, The First Hospital of Sun Yat-sen University  
- Professor Zhu Guoxian, Shenzhen Second People's Hospital  
- Professor Zhang Yan, The First Hospital of Jinan University

Presentations: Professor Wang Haiyang**, The First Hospital of Guangzhou Medical University:

“Revisiting the Anatomy of Lower Extremity Varicose Veins from the Perspective of Endovenous Radiofrequency Therapy”


Professor Jian Zhaocheng**,Hospital of Shandong Second Medical University:

"Key Details and Points in Radiofrequency Ablation Procedures"


Commentary by:  
- Professor Chen Quan, Dongguan People's Hospital  
- Professor Ge Hongwei, Changzhou First People's Hospital  
- Professor Xu Zhongyou, Ningbo University of People's Hospital  
- Professor Ye Kaichuang, The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine



Participation in SEC 2024 provided EverBridge Group's peripheral vascular business unit with an excellent platform to showcase its brand, engage in enthusiastic interactions with experts, and explore new insights in the field. By learning the key points of peripheral vascular disease Treatment and gaining a deeper understanding of market demands and pain points, the group has laid a solid foundation and direction for future product iterations and the refinement of comprehensive solutions. Moving forward, EverBridge Group's peripheral vascular business unit will continue to strive for excellence, contributing to the diagnosis, Treatment, and service of peripheral vascular diseases, and benefiting both medical professionals and patients alike.